Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

Background Currently, the data regarding the effectiveness and safety of tocilizumab as
treatment for COVID-19 infection is still conflicting. This study aims to give clear evidence …

The pleiotropic cytokine interleukin-6 (IL-6) is involved in numerous physiological and
pathophysiological functions that include development, immune cell differentiation …

Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …

Introduction We systematically assessed benefits and harms of tocilizumab (TCZ), which is
an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients. Methods Five …

We performed a meta-analysis to determine safety and efficacy of tocilizumab in persons
with coronavirus disease-2019 (COVID-19). We searched PubMed, Web of Science and …

The vascular endothelial injury occurs in severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infections, but the mechanisms are poorly understood. We sought to …

Since December 2019, a novel coronavirus that represents a serious threat to human lives
has emerged. There is still no definite treatment for severe cases of the disease caused by …

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has
become a pandemic that took more than 2 million lives. There are numerous ongoing …

Objective: This meta-analysis aims to assess the efficacy and safety of
granulocytemacrophage colony-stimulating factor (GM-CSF) antibodies on COVID-19 …